Visura Technologies Announces Strategic Expansion of Executive Leadership Team

 // News

March 25  

Commercial and Business Development team to accelerate the adoption of TEECAD at heart centers across the US

MINNEAPOLIS, March 25, 2023 —  Visura Technologies Inc., a privately owned medical device company based in Minneapolis dedicated to delivering state-of-art visualization solutions to improve the safety and success of TEE probe intubation announced today the addition of three seasoned medical device leaders to the executive team to drive growth of the TEECAD system across the United States.  

Jenna Schuetzle joins the team as Vice President of Marketing and Clinical Sales. Ms. Schuetzle brings nearly 20 years of progressive medical device sales and marketing experience to the team. Jenna’s experience and leadership ranges from mid-to-large size medical device organizations including Coloplast, Penumbra, Cardiovascular Systems Inc. (CSI), and Abbott Vascular. At Abbott Vascular, she led the Midwest sales organization to the top performing coronary division within the company.  At CSI, she led the launch of coronary atherectomy, achieving 70% market penetration. In her role at Visura, Ms. Schuetzle will lead the sales and marketing organization to achieve key commercial milestones towards expanding product adoption of TEECAD. 

To support the expansion of TEECAD, Andrea Richter joins Visura as Vice President of Commercial Operations. Ms. Richter brings over 20 years of medical device sales operations leadership experience to Visura. Andrea’s professional experience includes emerging growth companies all the way through merger and acquisition activities at large organizations. With corporate experience at Nellcor-Puritan-Bennet-Tyco-Mallickrodt, Nonin, and Crest, Ms. Richter has led sales operations teams that have experienced rapid growth and delivered over $90M in annual revenue. At Visura, she will drive operational excellence and efficiency to ensure optimal customer satisfaction with the TEECAD solution. 

Jodi Lamberti has been with Visura as a commercial consultant since early 2022 and is transitioning to the executive leadership team as Vice President of Business Development.  In this role Ms. Lamberti will build strategic relationships with key industry and clinician partners to further expand the reach of TEECAD and drive the growth of the organization. Ms. Lamberti has worked with start-ups in the medical device industry for over 15 years and has a proven track record of building successful commercialization programs to accomplish key business milestones and grow valuation. She has supported companies through IPOs on Australian and US markets as well as a successful acquisition by a global medical device corporation.

“Having these three strong and experienced leaders as part of our executive team will take the tremendous commercial progress that Visura made in 2023 to the next level”, stated Christine Horton, President and Chief Executive Officer of Visura Technologies. “The addition of commercial expertise to our executive team positions Visura to execute on our mission to deliver TEE innovation and improved safety and efficiency to patients around the world. I am excited by the potential of this powerhouse team and have already seen the impact their contributions are making to rapidly grow Visura.”


Visura’s TEECAD System is the world’s first, FDA-cleared disposable camera that seamlessly connects to TEE probes to provide real-time visualization during esophageal intubation for more efficient and effective probe placement. There are an estimated 1.7M TEE procedures performed annually in the U.S. with TEE procedures growing at an annual rate of 10%.

About Visura
Visura is a privately held medical device company dedicated to delivering state-of-art visualization solutions to improve the safety and success of TEE probe intubation. They have developed the TEECAD System, the world’s first and only, FDA-cleared, disposable camera that seamlessly connects to a TEE probe, providing physicians real-time visualization for more efficient and effective probe placement to support safer intubation. For more information, please visit

Success message!
Warning message!
Error message!